Switching from Wegovy Injections to Wegovy Tablets: What You Need to Know

Switching from Wegovy Injections to Wegovy Tablets: What You Need to Know

As Wegovy tablets become available in the UK, many patients currently using Wegovy injections are asking whether they can switch from the weekly injection to the once-daily tablet.

Both treatments contain the same active ingredient, semaglutide. The main difference is how the medication is delivered. Wegovy injections are administered once weekly under the skin, while Wegovy tablets are taken orally once daily.

For some patients, the tablet may offer a more convenient alternative to injections. However, any switch should be discussed with a healthcare professional to ensure the most appropriate dose, timing and treatment plan.

Can You Switch from Wegovy Injections to Wegovy Tablets?

Yes. Patients who are currently using Wegovy injections may be suitable for switching to Wegovy tablets following a clinical assessment.

Because both treatments contain semaglutide, the aim of switching is to maintain the benefits of treatment while using a different method of administration.

Some patients prefer tablets because they:

• Do not like injections or needles
• Travel frequently
• Prefer a daily medication routine
• Want an alternative to self-injecting each week

Others may choose to remain on injections because they prefer the convenience of a once-weekly treatment schedule.

How Do Wegovy Tablets Work?

Wegovy tablets contain semaglutide, a GLP-1 receptor agonist.

Semaglutide works by mimicking a naturally occurring hormone called glucagon-like peptide-1 (GLP-1). This helps:

* Increase feelings of fullness
* Reduce hunger
* Slow stomach emptying
* Support reduced calorie intake

As with Wegovy injections, tablets should be used alongside healthy eating habits, increased physical activity and ongoing clinical support.

How to Switch from Wegovy Injections to Wegovy Tablets

Many patients ask when they should start Wegovy tablets after stopping Wegovy injections.

According to Novo Nordisk prescribing guidance, patients taking Wegovy injections may be able to switch to Wegovy tablets. The correct tablet dose depends on the current injection dose and individual clinical circumstances.

The usual approach is:

1. Take your final Wegovy injection.
2. Wait 7 days.
3. Start your prescribed Wegovy tablet dose on the day your next injection would have been due.

This approach helps maintain consistent semaglutide exposure while moving from a weekly injection to a daily tablet.

The most appropriate tablet strength will depend on your current Wegovy dose and your healthcare professional's advice.

Wegovy Injection to Tablet Dose Conversion Guide

The appropriate Wegovy tablet strength depends on your current Wegovy injection dose. Patients should generally be established on their current Wegovy injection dose for at least 4 weeks and be tolerating treatment well before considering a switch to Wegovy tablets. Any switch should only be made following assessment and advice from a qualified healthcare professional.



Your clinician will advise the most appropriate starting tablet strength based on your treatment history, weight management goals and individual circumstances.

Wegovy Tablet Dose Escalation Schedule

Wegovy tablets are available in four strengths and are designed to be increased gradually to help improve tolerability.



If side effects occur during dose escalation, your clinician may recommend remaining on the current dose for longer before increasing.

How Should Wegovy Tablets Be Taken?

For Wegovy tablets to work effectively, they should be taken exactly as directed.

The tablet should usually be taken:

• Once daily
• First thing in the morning
• On an empty stomach
• With a small amount of plain water
• At least 30 minutes before food, drink or other oral medications

Following these instructions helps maximise absorption of semaglutide.

What Should I Expect When Switching?

Most patients should not notice a dramatic difference in appetite control when moving between equivalent doses of semaglutide.

However, some people may notice temporary changes as their body adjusts to a different method of delivery.

Common side effects may include:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Indigestion
• Abdominal discomfort

These side effects are generally similar to those experienced with Wegovy injections and often improve over time.

Our Clinical Approach to Dose Escalation

At Pharmulous, we do not automatically recommend increasing your medication dose if your current dose is working effectively for you.

Our clinical approach is based on using the lowest effective dose that helps you achieve your weight management goals, whether you are using Wegovy injections, Wegovy tablets or another GLP-1 treatment.

Remaining on the lowest effective dose may help:

• Reduce the risk of side effects
• Support steady and sustainable weight loss
• Improve long-term treatment adherence
• Keep treatment costs as manageable as possible

Dose increases should only be considered when clinically appropriate and when the current dose is no longer providing the desired effect.

Every patient responds differently to treatment. Some people may require higher doses to achieve or maintain their results, while others continue to do well on lower doses for extended periods.

Our prescribing clinicians will review your progress regularly and recommend dose changes only when they are likely to provide a meaningful clinical benefit.

Will I Continue Losing Weight?

Clinical studies suggest that oral semaglutide can produce significant weight loss when combined with diet and lifestyle changes.

The OASIS 4 phase 3 clinical trial evaluated oral semaglutide 25mg in adults living with obesity or overweight. Participants achieved average weight loss of approximately 14% over 64 weeks when analysed regardless of treatment adherence.

Among participants who remained on treatment as intended, average weight loss reached approximately 16.6%, with around one-third of participants achieving weight loss of 20% or greater.

For comparison, the STEP 1 trial evaluating Wegovy 2.4mg injections reported average weight loss of approximately 15% over 68 weeks.

Results vary from person to person and ongoing success depends on medication adherence, dietary habits, physical activity and long-term lifestyle changes.

How Does Weight Loss with Wegovy Tablets Compare to Wegovy Injections?

The chart below summarises average weight loss reported in the major clinical studies for oral semaglutide tablets and Wegovy injections.

Clinical Evidence Behind Wegovy Tablets

Wegovy tablets contain oral semaglutide, the same active ingredient found in Wegovy injections.

The OASIS 4 phase 3 clinical trial evaluated oral semaglutide 25mg in adults living with obesity or overweight. Participants achieved average weight loss of approximately 14% over 64 weeks, while those who remained on treatment achieved average weight loss of approximately 16.6%.

Around one-third of participants achieved weight loss of 20% or more.

Earlier research from the OASIS 1 trial also demonstrated substantial weight loss with higher-dose oral semaglutide when combined with diet and lifestyle changes.

These studies demonstrate that oral semaglutide can be an effective option for eligible patients seeking medical weight management support.

Can I Switch Back from Wegovy Tablets to Wegovy Injections?

Yes. According to manufacturer guidance, patients taking Wegovy 25mg tablets may be able to start Wegovy injections the day after their final tablet dose.

Unlike switching from injection to tablet, a 7-day waiting period is generally not required when moving from tablets back to injections.

The typical approach is:

1. Take your final Wegovy tablet.
2. Start your prescribed Wegovy injection the following day.
3. Continue treatment according to your clinician's instructions.

If Wegovy tablets are not suitable or become difficult to maintain, your healthcare provider can discuss alternative options, including switching back to injections where appropriate.

Any treatment change should always be supervised by a qualified healthcare professional.

When Should I Seek Medical Advice?

Contact your healthcare provider if you experience:

• Persistent nausea or vomiting
• Severe diarrhoea or constipation
• Difficulty maintaining hydration
• Symptoms that interfere with your daily activities
• Concerns about your weight loss progress

Seek urgent medical attention if you experience:

• Severe abdominal pain
• Signs of an allergic reaction
• Difficulty breathing
• Severe dehydration
• Symptoms that feel serious or unusual for you

Frequently Asked Questions

Are Wegovy tablets available in the UK and can I switch from injections?

Yes. Wegovy tablets have been approved in the UK for weight management in eligible adults. Patients currently using Wegovy injections may be suitable for switching following a clinical assessment.

Are Wegovy tablets the same as oral semaglutide?

Yes. Wegovy tablets contain semaglutide, the same active ingredient used in Wegovy injections. The difference is that Wegovy tablets are taken once daily, while Wegovy injections are administered once weekly.

Can I switch from Wegovy 2.4mg injections to Wegovy tablets?

Some patients taking Wegovy 2.4mg injections may be suitable for switching to Wegovy tablets following a clinical assessment. The appropriate tablet dose and timing should be determined by a healthcare professional.

Which is better: Wegovy injections or Wegovy tablets?

Both formulations contain semaglutide and can support weight loss when used alongside lifestyle changes. The most suitable option depends on individual preference, tolerability, medical history and clinical circumstances.

Can I buy Wegovy tablets online?

Wegovy tablets are prescription-only medicines. Patients must complete an appropriate clinical assessment before treatment can be prescribed if clinically suitable.

Key Takeaways

• Wegovy injections and Wegovy tablets both contain semaglutide.
• Many patients may be suitable for switching from injections to tablets following a clinical assessment.
• Patients typically start Wegovy tablets 7 days after their final injection.
• Patients switching back to injections may be able to start the day after their final tablet.
• Wegovy tablets are taken once daily and should be taken on an empty stomach.
• Oral semaglutide has demonstrated significant weight loss in clinical trials.
• Pharmulous recommends remaining on the lowest effective dose whenever clinically appropriate.
• The most appropriate dose and switching strategy should always be determined by a healthcare professional.

References

References

1. Wharton S, et al. Oral Semaglutide 25 mg for Weight Management in Adults with Overweight or Obesity (OASIS 4). New England Journal of Medicine. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2302392

2. O'Neil PM, et al. Oral Semaglutide 50 mg Once Daily in Adults with Overweight or Obesity (OASIS 1). The Lancet. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01185-6/fulltext

3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

4. Medicines and Healthcare products Regulatory Agency (MHRA). GLP-1 medicines: information for patients. Available at: https://www.gov.uk/government/publications/glp-1-receptor-agonists-information-for-patients

5. Novo Nordisk. Wegovy Summary of Product Characteristics (SmPC). Available at: https://www.medicines.org.uk/emc/product/13801

6. National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity. Available at: https://www.nice.org.uk/guidance/ta875